UroGen Pharma Ltd. — Director's Dealing 2023

Sep 5, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2023-08-31

Reporting Person: Smith Jason Drew (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-31	Ordinary Shares	M	8334	—	Acquired	22207	Direct
2023-08-31	Ordinary Shares	S	3800	$18.01	Disposed	18407	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-08-31	Restricted Stock Units	$	M	8334	Disposed		Ordinary Shares (8334)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F3: The reporting person was granted RSUs on August 31, 2020 representing 25,000 ordinary shares. The RSUs vested in three equal installments on November 30, 2021, August 31, 2022 and August 31, 2023.